FDA Adverse Event Death Summary report: N

ACL TOP CTS

MDR report key: 1512560 · Received October 16, 2009

Report

Report Number
1217183-2009-00003
Event Type
Death
Date Received
October 16, 2009
Date of Event
September 3, 2009
Report Date
October 16, 2009
Manufacturer
INSTRUMENTATION LABORATORY CO.
Product Code
JPA
PMA / PMN Number
K073377
Removal / Correction Number
NA
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
IL, US
Reporter Occupation
OTHER HEALTH CARE PROFESSIONAL

Narratives

Additional Manufacturer Narrative · 1

AN IL INVESTIGATION IS CURRENTLY UNDERWAY REGARDING THIS COMPLAINT, AND THE ACL TOP BACKUP AND PRINTOUTS HAVE BEEN REQUESTED FROM THE CUSTOMER. ONCE THE INVESTIGATION IS COMPLETE, WE WILL SUBMIT A FOLLOW-UP REPORT WITH THE RESULTS.

Description of Event or Problem · 1

CUSTOMER REPORTED THAT A PT WITH AN APTT RESULT OF 89 SEC. HAD A CEREBRAL HEMORRHAGE. THE CUSTOMER WAS HAVING ISSUES WITH HEPARIN DOSAGE AND THEIR APTT HEPARIN RANGE. THEY HAD RECENTLY STARTED USING A NEW LOT OF HEMOSIL SYNTHASIL (APTT REAGENT) ON THEIR ACL TOP CTS (CLOSED TUBE SAMPLING) COAGULATION ANALYZER, AND THIS CHANGED THEIR HEPARIN RANGE SLIGHTLY FROM 65.0-120.0 SEC. TO 73.0-125.0 SEC. AFTER PERFORMING A HEPARIN RANGE STUDY. CUSTOMER ALSO REPORTED EXPERIENCING PTS THAT ARE ON HEPARIN AND THE APTT OF 31 SEC. AND THE ANTI-XA FOR UF IS 0.09. PER THE CUSTOMER, THEY ARE USING HOMEMADE QC MATERIAL FOR THE HEPARIN ASSAY. THEIR 0.3 QC GIVES A VALUE OF 0.28 AND THE 0.6 QC GIVES A VALUE OF 0.58. THEREFORE, THE ASSAY IS READING CORRECTLY. WHEN HEMOSIL SYNTHASIL WAS RUN ON THE ACL TOP CTS WITH THE HOMEMADE QC, THE RESULTS WERE 85 SEC. ON THE 0.3 QC AND > 150 SEC. ON THE 0.6 QC, WHICH ARE OUTSIDE THE ESTABLISHED RANGE. THERE WAS A QUESTION IF THEY COULD DO THIS BECAUSE THE QC MATERIAL IS NORMAL POOLED PLASMA SPIKED WITH HEPARIN AND THE RANGE WAS BASED ON ACTUAL PT SAMPLES.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 ACL TOP CTS COAGULATION ANALYZER JPA INSTRUMENTATION LABORATORY CO. 2800-20 NA

Patients

Seq Age Sex Outcome Treatment
1 UNK Death